| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SLC25A6 |
| Uniprot No | P12236 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 232-272aa |
| 氨基酸序列 | DTVRRRMMMQSGRKGADIMYTGTVDCWRKIFRDEGGKAFFK |
| 预测分子量 | 20.2 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于SLC25A6重组蛋白的示例参考文献(注：以下为模拟内容，建议通过学术数据库查询真实文献)：
---
1. **标题**：*Recombinant expression and functional analysis of human SLC25A6 in yeast mitochondria*
**作者**：G. Ruprecht et al.
**摘要**：研究通过酵母表达系统重组表达了人源SLC25A6蛋白，验证其在线粒体中的ADP/ATP转运活性，并发现其功能受膜电位调控。
2. **标题**：*Crystal structure of the SLC25A6-ATP complex reveals substrate recognition mechanism*
**作者**：K. Tanaka et al.
**摘要**：报道了重组SLC25A6蛋白的晶体结构，揭示了ATP结合的关键氨基酸残基，为理解转运机制提供结构基础。
3. **标题**：*SLC25A6 recombinant protein rescues mitochondrial dysfunction in cellular models*
**作者**：L. Martínez et al.
**摘要**：利用重组SLC25A6蛋白在细胞模型中恢复线粒体膜电位和能量代谢，证明其在治疗线粒体疾病中的潜在应用。
4. **标题**：*Comparative kinetics of recombinant SLC25A6 isoforms in liposome-based transport assays*
**作者**：S. Park et al.
**摘要**：通过脂质体包裹重组SLC25A6异构体，比较不同剪接变体的ADP/ATP转运效率，发现组织特异性功能差异。
---
建议通过PubMed或Google Scholar搜索关键词“SLC25A6 recombinant protein”或“SLC25A6 expression/purification”获取真实文献。
SLC25A6. also known as adenine nucleotide translocase 1 (ANT1), is a member of the solute carrier family 25 (SLC25), which comprises mitochondrial carrier proteins responsible for transporting metabolites, nucleotides, and cofactors across the mitochondrial inner membrane. As a key component of cellular energy metabolism, SLC25A6 facilitates the exchange of ADP and ATP between the mitochondrial matrix and cytosol, a critical process for maintaining ATP homeostasis and supporting cellular functions. It is predominantly expressed in tissues with high energy demands, such as the heart, skeletal muscle, and liver.
The recombinant SLC25A6 protein is engineered through molecular cloning and heterologous expression systems (e.g., E. coli or mammalian cells) to study its structural and functional properties. This approach enables researchers to investigate its role in mitochondrial physiology, including its involvement in oxidative phosphorylation, apoptosis regulation, and potential links to diseases. Structural studies reveal that SLC25A6 forms a homodimer with six transmembrane helices, featuring conserved motifs critical for substrate binding and transport.
Dysregulation of SLC25A6 has been associated with mitochondrial disorders, cancer, and metabolic syndromes. Recombinant versions are widely used in biochemical assays to screen modulators or analyze mutations affecting transport activity. Additionally, recombinant SLC25A6 serves as a tool to explore its interaction with ligands like the pro-apoptotic protein Bax or the adenine nucleotide translocase inhibitor carboxyatractyloside.
The production of recombinant SLC25A6 often faces challenges such as maintaining proper folding and membrane integration due to its hydrophobic nature. Advanced expression systems and purification strategies (e.g., affinity chromatography, detergent solubilization) are employed to obtain functional protein for in vitro studies. Ongoing research aims to elucidate its regulatory mechanisms and therapeutic potential in mitochondrial dysfunction-related diseases.
×
